Kornimate/medical-research-clean huggingface dataset:
effectiveness of hiv risk reduction program among african american men

Conditions: Sexually Transmitted Diseases; HIV

Summary: this study will test the effectiveness of a brief clinic-based program designed to promote the correct use of condoms among young african-american men newly diagnosed with a sexually transmitted disease.

sexually transmitted diseases (stds), including hiv infections, are most commonly spread through unprotected sexual intercourse. stds are a major health concern, especially among young ethnic minorities in the united states. the rate of stds is significantly greater in urban areas where ethnic minorities, particularly african-american males, are commonly represented. despite this knowledge, safe sexual practices, including correct condom use, are not the norm among minority males. it is believed that educational outreach designed to motivate and inform on the correct use of condoms will be effective in encouraging safer sex practices. this study will test the effectiveness of a brief clinic-based program designed to promote the correct use of condoms among young african-american men newly diagnosed with an std. participants in this single blind study will be randomly assigned to an experimental or control group. upon being diagnosed with an std, men in both groups will receive standard of care follow-up treatment. men in the experimental group will also receive a one-on-one educational session on condom use. the educational session will be led by a health educator and will last about 30 minutes, depending on the existing skills and learning abilities of the participants. using information provided by the participants on past experience with condoms, the health educator will attempt to correct misunderstandings about and problems with condom use. upon enrollment, all men will respond to a series of pre-recorded questions and will be required to demonstrate their ability to apply condoms to a penile model. the same questions and procedure will be repeated 3 months later.

Eligibility criteria:
inclusion criteria: * identifies as african american * clinically diagnosed with an std * reports at least one episode of condom use with a female within 3 months of study entry (this requirement does not restrict men who also have sex with men from study participation) * fluent in english exclusion criteria: * known hiv infection

Keywords: african american men sexually transmitted diseases condoms
optimal management of pain in hospitalized patients - opioid tolerant populations.

Conditions: Pain; Acute Pain; Postoperative Pain

Summary: pain is a symptom that drives hospital admissions, and pain management is required by most patients during their hospital stay. further, the use of medications such as opioids can lead to upward-spiraling doses, especially among chronic pain patients whose resource utilization rates are high. many initiatives aim to reduce the costs of these "high-resource utilizing" patients. one exciting aspect of improving the management of pain is that this may help prevent patients from ever becoming high-cost in the first place. the purpose of this study is to examine the impacts of an early and sustained intervention pathway, in comparison to the current standard of care, for the treatment of pain in opioid tolerant patients. it is hypothesized that patients randomized to the intervention pathway, in comparison to the control, will lead to decreased costs of care, a reduction in opioid usage within 3 and 6 months, and decrease in hospital readmission rates.


Eligibility criteria:
inclusion criteria: * adult patients (18 years and older) * known opioid tolerant (as determined per fda criteria) * agree to sign the informed consent and hipaa forms exclusion criteria: * patients under the age of 18 years * no known opioid tolerance * do not agree to sign the informed consent and hipaa forms

Keywords: patient readmission pain relief units pain centers multidisciplinary pain clinics multidisciplinary pain centers pain clinics hospital readmission emergencies emergency medicine critical care emergency treatment opioid acute pain service
correlation of gene status and clinical outcomes in escc

Conditions: Prognosis of Patients With ESCC

Summary: the incidence of esophageal squamous cell carcinoma is highly regional and familial. the current treatment plan is based on the stage and location of the tumor.by studying the relationship between the status of different genes and prognosis, it can help doctors to develop precise and individualized treatment plans.


Eligibility criteria:
inclusion criteria: * esophageal cancer patients who underwent surgery treatment, and postoperative pathological diagnosis was squamous cell carcinoma. patients with escc have complete clinical information. exclusion criteria: * patients who also suffering from other tumors.
evaluation of gender differences on the psychosocial and economic impact in patients with advanced non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this study is to evaluate of gender differences on the psychosocial and economic impact in patients with advanced non-small cell lung cancer.

multi-centre, prospective follow-up post-authorisation study of two patient cohorts with metastatic nsclc (men and women). it will be stratified based on biological sex, age and smoking to guarantee homogeneity between the cohorts. the clinical procedures for assessing the tumour and the treatment response will be performed according to the site's standard practice.

Eligibility criteria:
inclusion criteria: * patients diagnosed with stage iv nsclc who are going to commence first line treatment * patients over the age of 18 * ecog 0-3 * patients who have granted their informed consent, preferably in writing, but otherwise, verbal with witnesses who are independent of the research team * life expectancy of over three months * speak fluent spanish, in order to be able to complete the study questionnaires * patients able to read and write with no problems exclusion criteria: * previous systemic treatment for metastatic nsclc. the administration of neoadjuvant or adjuvant radiotherapy and/or chemotherapy is permitted provided it was completed major or equal 6 months prior * dementia or a significantly altered mental state that could affect comprehension or the ability to grant informed consent
ahmed glaucoma valve and single-plate molteno implants in treatment of refractory glaucoma

Conditions: Refractory Glaucoma

Summary: the purpose of this study is to investigate the efficacy and safety of the ahmed valve implant (avi) and the molteno single-plate implant (mspi) in eyes with refractory glaucoma during a follow-up period of 24 months.


Eligibility criteria:
inclusion criteria: * refractory glaucoma, defined as uncontrolled iop despite maximal anti-glaucoma medication, previously failed nonseton surgical treatment, or a combination thereof. exclusion criteria: * age less than 40 years * a visual acuity of no light perception * lens opacity * elevated iop associated with silicone oil previous glaucoma drainage device implantation in the same eye * previous cyclodestructive treatment * increased risk of endophthalmitis posterior segment disorders * pre-existing ocular comorbidities.

Keywords: ahmed valve single-plate molteno implant refractory glaucoma surgical treatment
vildagliptin for treatment of antipsychotic-induced dyslipidemia

Conditions: Schizophrenia; Dyslipidemias

Summary: almost all antipsychotics can induce dyslipidemia, but no treatment has been established. vildagliptin can improve lipid levels in obese patients. the investigators conducted a randomized, placebo-controlled study to test the efficacy of vildagliptin for antipsychotic-induced dyslipidemia.


Eligibility criteria:
inclusion criteria: * diagnostic and statistical manual of mental disorder-fourth edition (dsm-ⅳ) criteria for schizophrenia dyslipidemia after antipsycotic treatment the duration of illness was less than 12 months taking only one antipsychotic stable outpatient the total score of positive and negative syndrome scale (panss)≤60. exclusion criteria: * liver or renal diseases pregnant or lactating women cardiovascular diseases hypertension or diabetes mellitus
autologous fat graft alleviate scar pain

Conditions: Scar

Summary: traumatic wounds inflict small- and large-fiber sensory nerve damage, causing neuropathic pain in scar tissue. autologous fat grafting has been clinically shown to improve scar quality, but scantly study has explored its effects on pain. the aim of the study was to survey its effect on pain.

methods: from february 2008 and june 2013, a total of 36 patients received autologous fat grafting in scar areas. patients who douleur neuropathique 4 questions (scores \>4/10) were enrolled this study. the visual analogue scale (vas), and neuropathic pain symptom inventory (npsi) were used to evaluate pain preoperatively and postoperatively after 1 week, 4 weeks, and 24 weeks. the mechanism of trauma, duration of allodynia, fat graft volume, and total follow-up time were recorded.

Eligibility criteria:
inclusion criteria: * february 2008 and june 2013, patients received autologous fat grafting in scar areas and also had pain over scar area before surgery exclusion criteria: * patients refused to participate the study
efficacy, safety, and tolerability of dupilumab in patients with persistent moderate to severe eosinophilic asthma

Conditions: Asthma

Summary: primary objective: to investigate the effects of dupilumab (sar231893/regn668) administered subcutaneously (sc) once weekly (qw) for 12 weeks as compared to placebo on reducing the incidence of asthma exacerbation in participants with persistent moderate to severe eosinophilic asthma. secondary objectives: * to assess the safety and tolerability of dupilumab administered sc qw for 12 weeks in participants with persistent moderate to severe eosinophilic asthma. * to assess dupilumab serum concentrations following qw sc dosing for 12 weeks in participants with persistent moderate to severe eosinophilic asthma.

the total duration of the study period per participant was 20-22 weeks broken down as follows: * screening period: up to 14 days, * treatment period: 12 weeks, * follow-up period: 6-8 weeks.

Eligibility criteria:
inclusion criteria: medical diagnosis of persistent asthma for at least 12 months whose: * airway inflammation likely to be eosinophilic, * asthma partially controlled or uncontrolled on ics plus laba therapy. * on a stable dose of either fluticasone/salmeterol, budesonide/formoterol, mometasone/formoterol combination therapy for at least 1 month prior to screening. * signed an informed consent form and health insurance portability and accountability act (hipaa) authorization form. exclusion criteria: * less than 18 years or greater than 65 years of age. * clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further evaluation. * chronic obstructive pulmonary disease and/or other lung diseases impairing pulmonary function tests. * beta-adrenergic receptor blockers required for any reason. * current smoker or cessation of smoking within the 6 months prior to screening. * previous smoking with a smoking history \>10 cigarette pack/years. * participation in another study within 6 months prior to screening if the study medication was an antibody or within 30 days prior to screening for all other study medications. * known or suspected non-compliance, alcohol or drug abuse. * inability to follow the procedures of the study (e.g, due to language problems, psychological disorders). * concomitant severe diseases or diseases for which the use of ics or laba were contraindicated. * known allergy to doxycycline or related compounds. * pregnancy or intention to become pregnant during the course of the study, breast feeding, or unwillingness to use a highly effective method of contraception throughout the study in women of childbearing potential. * recent history of a parasitic infection or travel to a parasitic endemic area within 6 months prior to screening. the above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
laparoscopic versus open gastrectomy with splenic hilum lymph nodes dissection

Conditions: Gastric Cancer

Summary: splenic hilum remains challenging during total gastrectomy with d2 lymphadenectomy.the application of minimally invasive surgery for advanced gastric cancer is gaining popularity. the investigators aim to compare the safety and feasibility of ltg and otg for advanced proximal gastric cancer.

total gastrectomy with d2 lymphadenectomy remains the standard surgical therapy for patients with advanced proximal gastric cancer. although lymph nodes dissection along with the splenic hilum (no.10) is recommended by the japanese gastric cancer treatment guidelines, however, complete removal of the no. 10 is technically challenging due to the tortuous splenic vessels and the high possibility of injury to the parenchyma of the spleen and pancreas. recently, the application of minimally invasive surgery for advanced gastric cancer is gaining popularity. however, laparoscopic total gastrectomy (ltg) with standard d2 lymphadenectomy was still not widely performed, because pancreas- and spleen-preserving splenic hilum lymph node dissection were mainly challenging manipulations for laparoscopic surgeons. therefore,the investigators aim to investigate the safety and feasibility of ltg with spleen-preserving splenic hilum lymph node dissection for proximal advanced gastric cancer and compare the early results of this procedure with open total gastrectomy (otg).

Eligibility criteria:
inclusion criteria: 1. primary proximal gastric adenocarcinoma confirmed pathologically by endoscopic biopsy; 2. ct2-4an0-3m0 at preoperative evaluation according to american joint committee on cancer (ajcc) cancer staging manual, 7th edition. 3. eastern cooperative oncology group (ecog): 0 or 1; 4. american society of anesthesiologists （asa） score: ⅰto ⅲ; 5. written informed consent. exclusion criteria: 1. pregnant or breast-feeding women; 2. severe mental disorder; 3. previous upper abdominal surgery (except laparoscopic cholecystectomy); 4. previous gastrectomy, endoscopic mucosal resection, or endoscopic submucosal dissection; 5. enlarged or bulky regional lymph node diameter larger than 3 cm based on preoperative imaging; 6. other malignant disease within the past 5 years; 7. previous neoadjuvant chemotherapy or radiotherapy; 8. contraindication to general anesthesia (severe cardiac and/or pulmonary disease); 9. emergency surgery due to a complication (bleeding, obstruction, or perforation) caused by gastric cancer.

Keywords: gastric cancer splenic hilum lymph nodes dissection gastrectomy
long-term safety follow-up of subjects previously enrolled in rheumatoid arthritis studies of cp-690,550

Conditions: Arthritis, Rheumatoid

Summary: the purpose of this study is to follow the health of subjects who have previously been enrolled in studies of cp-690,550 for treatment of their rheumatoid arthritis. subjects are only eligible for this study after they have completed all participation in other studies of cp-690,550.

at their last visit of a qualifying study, eligible subjects will be given the opportunity to participate in this study.

Eligibility criteria:
inclusion criteria: * subjects who have completed all participation in any other phase 2b or phase 3 studies of cp-690,550 for rheumatoid arthritis. exclusion criteria: * any subject who refuses consent.

Keywords: observational non-interventional long-term safety
the effect of continuous glucose monitoring in surgical patients with diabetes.

Conditions: Diabetes Mellitus; Dysglycemia; Perioperative Complication

Summary: the goal of this randomised controlled trial to investigate the effect of continuous glucose monitoring (cgm) compared to standard point-of-care (poc) blood glucose measurements in surgical patients with diabetes in patients. the main question it aims to answer is: • can the use of the cgm device dexcom g7 with real-time alerts on dysglycaemia increase the time in range for glucose levels as compared with standard monitoring with point-of-care blood glucose in surgical patients with diabetes? participants will be asked to wear a cgm device (dexcom g7, dexcom inc.) during their stay in the hospital. for patients in the intervention group, deviations of glucose levels will provide the nursing staff with alerts. all patients will receive standard care of their diabetes. the cgm device will be worn for up to 10 days or until discharge.

this is a prospective randomised controlled multicentre trial on patients living with diabetes who undergo surgery at rigshospitalet, copenhagen university, bispebjerg and frederiksberg hospital, copenhagen university, and zealand university hospital, køge, denmark the study aims to investigate the effect of the cgm-device dexcom g7 cgm in patients with diabetes undergoing surgery on the diabetic control. the dexcom g7 provides glucose readings every 5 minutes and can send alerts on dysglycaemia (hypo- and hyperglycaemia) to mobile devices held by the nursing staff. patients will wear the cgm before, during and up to 10 days postoperatively. the study will include 200 patients. this study is part of an overall project that aims to investigate the use of cgm and continuous wireless monitoring of vital signs in patients with diabetes undergoing major surgery. using this technology, postoperative complications including dysglycaemia can potentially be detected and treated earlier thus improving the perioperative care.

Eligibility criteria:
inclusion criteria: * medical history with diabetes mellitus (dm1 or dm2 (insulin-dependent and non-insulin-dependent) requiring antidiabetic drug(s) * acute or elective abdominal, orthopaedic, urological, or vascular surgery with estimated duration of surgery \>45 minutes * expected stay for at least one night in the hospital postoperatively exclusion criteria: * local skin symptoms including infection at the posterior aspect of the upper arm that does not allow the sensor to be placed on an unaffected skin area * known allergy to the equipment plaster * known pregnancy * patients with pacemaker or implantable cardioverter defibrillator (icd) device * previous or currently scheduled for pancreatectomy (complete or partial) * patients receiving hydroxyurea (these drugs may interfere with cgm readings)

Keywords: diabetes mellitus continuous glucose monitoring perioperative medicine medical devices
study to assess the occurrence of hpa-1a alloimmunization in women with higher risk for fetal and neonatal alloimmune thrombocytopenia

Conditions: Fetal and Neonatal Alloimmune Thrombocytopenia

Summary: a prospective, non-interventional, natural history study to assess the occurrence of higher fnait risk across a broad population of different racial and ethnic characteristics and the occurrence of hpa-1a alloimmunization in these women.


Eligibility criteria:
inclusion criteria: * pregnant women (≥ 18 years of age) who have provided informed consent for the study. exclusion criteria: * participants with prior history of fnait

Keywords: alloimmunization hpa-1a fetal and neonatal alloimmune thrombocytopenia neonatal thrombocytopenia pregnant women
integrating pediatric tb services into child healthcare services in africa

Conditions: Tuberculosis; Children, Only; Diagnosis; Delivery of Health Care

Summary: under-diagnosis of tb in children is a critical gap to address. the input study is a multinational stepped-wedge cluster-randomized intervention study aiming to assess the effect of integrating tb services into child healthcare services on tb diagnosis capacities in children under 5 years of age.

study clusters (district-level hospitals and their health centers) will start under standard-of-care and transition to the intervention at randomly assigned time points. in this study two strategies will be compared: i) the standard of care, offering pediatric tb services based on current routine approach; ii) the intervention, with pediatric tb services integrated into child healthcare services. the primary objective will be to assess the effect of the intervention compared to standard of care on the proportion of tb cases diagnosed among children \<5 years old (that is the number of children who are clinically or bacteriologically diagnosed with tb over the total number of children attending the child healthcare services). secondary objectives are detailed in the protocol. study sites will include six hospital in each participating country (cameroon and kenya) along with selected attached health centers. the study population will be children aged less than five years of age with a presumptive diagnosis of tb. study enrollment will start in march 2019, last enrollments until july 2020 and follow up will be completed by august 2021.

Eligibility criteria:
inclusion criteria: * children \< 5 years old. * tb diagnosis investigations initiated. * other infectious diseases are not suspected or have already been ruled out. * commitment to take treatment in the clinic of enrolment or another input study site. * parental/caregiver consent for the child to participate in the study. exclusion criteria: * children who are tb contacts but without symptoms or signs of active tb
effects of upper limb motor and robotic training over neuroplasticity and function capacity

Conditions: Stroke

Summary: the purpose of this study is to evaluate and compare the effects of upper limb training with induced constraint therapy (ict) or robotic therapy. no placebo therapy is used. motor function, neurological evaluations and quality of life are assessed for the comparison of the therapies.

the trial is being carried out in the institute of physical medicine and rehabilitation of the university of são paulo since february 2012. the investigators are including patients with clinical diagnosis of ischemic or hemorrhagic stroke. the patients are being randomized in blocks of four, six and eight, in two arms: ict: patients are undergoing 60 minutes physiotherapy and occupational therapy twice a week for ten consecutive weeks. other therapeutic services as phonoaudiology, psychology, nutrition, physical conditioning are prescribed upon the patients' medical demands. after the 10 weeks, the patients are undergoing two whole weeks of daily ict as to reach 90% of the time under constraint, including weekends. during this last period, no other therapeutic service is offered, but the occupational therapy under ict. patients are not allowed to undergo robotic therapy. robotic therapy: patients are undergoing robotic occupational therapy for 60 minutes, three times a week for twelve consecutive weeks. all other therapeutic services are prescribed upon the patients' medical demands. patients are not allowed to undergo ict. the investigator and the raters are blind to treatment. the evaluations are done prior to the beginning of the treatment and at the end of it. the follow up assessments are done at 3 and 12 months after the end of the treatment. the sample size was estimated to be 62 patients in each arm, a total size of 124 patients

Eligibility criteria:
inclusion criteria: * clinical diagnosis of stroke; * patients from 6 months after stroke up to 36 months after stroke; * clinically stable; * upper limb brunnstrom scale iii or iv; * brunnstrom scale above v if clinician supports patients will benefit from treatment; * minimum wrist extension of 20°, and minimum of 10° of metacarpophalangeal active extension. * signed informed consent form; exclusion criteria: * mini-mental score lower than 20 points; * previous multiple strokes; * bone diseases and articulation injuries ; * presence of psychological disturbances capable of diminishing adherence; * articulation pain within the range of motion proposed by the therapies; * participation in another study protocol for upper limbs therapies. * previous treatment with robotic assisted therapies.

Keywords: induced constraint therapy robotic occupational therapy neuroplasticity